Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago
🌐 বাংলায় দেখুন

Indications

Type 2 Diabetes Mellitus Diabetes Mellitus

Pioglitazone + Glimepiride is a once-daily combination medicine used along with diet and exercise to improve blood sugar control in people with type 2 diabetes. It is meant for patients who are already treated with Pioglitazone and a sulfonylurea together, or whose diabetes isn't well controlled with a sulfonylurea alone. It also suits those who first responded to Pioglitazone alone but now need additional glycemic control.

⚠️ Always consult a registered physician before taking any medicine.

Pregnancy & Breastfeeding

Pioglitazone + Glimepiride is in pregnancy category C. Current information strongly suggests that abnormal blood glucose levels during pregnancy are linked to a higher rate of congenital anomalies and more illness and death in newborns. Because of this, most experts recommend insulin alone during pregnancy, so that blood glucose stays as close to normal as possible. The combination of Pioglitazone and Glimepiride should not be used during pregnancy.

Nursing mothers: No studies have been done with the combination of Pioglitazone and Glimepiride. It is not known whether Pioglitazone and/or Glimepiride pass into human milk. Many drugs do pass into human milk, so the combination should not be given to a breastfeeding woman.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The starting dose of Pioglitazone and Glimepiride depends on what the patient is already taking, Pioglitazone, a sulfonylurea, or both. Patients who may be more sensitive to antihyperglycemic drugs should be monitored carefully while the dose is being adjusted. A single dose of Pioglitazone and Glimepiride is recommended once daily with the first main meal. For patients currently on Glimepiride alone, the usual starting dose of Pioglitazone (15 mg or 30 mg daily) is the guide. The combination may be started at 30 mg/2 mg or 30 mg/4 mg tablet strength once daily, then adjusted after checking whether the therapeutic response is adequate. For patients currently on Pioglitazone alone, the guide is the usual starting dose of Glimepiride (1 mg or 2 mg once daily) along with Pioglitazone 15 mg or 30 mg. The combination may be started at 30 mg/2 mg once daily, then adjusted after checking whether the therapeutic response is adequate. For patients switching from Pioglitazone plus Glimepiride taken as separate tablets, the combination may be started at 30 mg/2 mg or 30 mg/4 mg, depending on the doses of Pioglitazone and Glimepiride they already take. Patients who are not controlled on 15 mg of Pioglitazone with Glimepiride should be monitored carefully when they move to the combination. For patients currently on a different sulfonylurea alone, or switching from Pioglitazone plus a different sulfonylurea, there is no exact dose relationship between Glimepiride and the other sulfonylurea agents. So the starting dose should be limited to 30 mg/2 mg once daily, based on the maximum starting dose of 2 mg Glimepiride. It is then adjusted after checking whether the therapeutic response is adequate.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.